% | $
Quotes you view appear here for quick access.

Pacific Sunwear of California Inc. Message Board

getmoney517365 8 posts  |  Last Activity: Mar 4, 2015 10:14 PM Member since: Jun 1, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • getmoney517365 by getmoney517365 Mar 4, 2015 10:14 PM Flag

    Shows over 3 mil on a three month average. over the last 30 days it doesn't appear to have broken two million. Buy and hold here. Interest is low but this isn't going much lower.

  • Reply to

    Preliminary Q4 Results?

    by getmoney517365 Mar 4, 2015 9:54 PM
    getmoney517365 getmoney517365 Mar 4, 2015 10:09 PM Flag

    Thanks. What you thinking on PPS from now till then?

  • getmoney517365 by getmoney517365 Mar 4, 2015 10:08 PM Flag

    Indeed, brachytherapy offers numerous advantages over other treatment options. It is as efficient as other treatment options, has fewer side effects and is cost effective. Given these factors, sooner rather than later, brachytherapy will become the treatment of choice for early stage prostate cancer.

    One of the most promising companies in the brachytherapy space is IsoRay Inc. (NYSEMKT: ISR), a Richland, Washington-based company engaged in the development, manufacture and sale of Cesium-131, a radioisotope used in brachytherapy.

    ISR’s Cesium-131 has numerous advantages over other radioisotopes. It has superior energy and the shortest half-life, which makes it an effective treatment option not just for prostate cancer but also for other forms of aggressive cancer.

    IsoRay’s sole focus over the past decade has been to increase awareness of Cesium-131 among the patient and the medical community. And it has been successful in this regard as evidenced by the company’s shares performance in 2014. Last year, ISR shares were among the top performers on the NYSEMKT, gaining more than 190%.

    The gains came on the back of some successful peer-reviewed studies that highlighted the effectiveness of Cesium-131.

    On Wednesday, ISR announced its financial results for the quarter ended December 31, 2014. At the end of the quarter, the company had $20 million in cash on its balance sheet and no debt. This is very unusual for an early-stage company like IsoRay. However, the financial situation highlights the astuteness of the management, which took advantage of the surge in stock price last year and completed a secondary offering.

    Given ISR’s robust cash position and current burn rate, the company will not need any additional cash for at least the next five years. This completely takes out the dilution risk, which is usually associated with early stage companies like IsoRay.

    On the operating front, the company has not been doing too badly either. It remains committed to diversifyi

    Sentiment: Strong Buy

  • getmoney517365 by getmoney517365 Mar 4, 2015 9:54 PM Flag

    Any idea when the real ones will be announced with year end results? Any rule or time frame from moment of uplisting? TIA

  • Reply to

    three milliom shares for 4.15?

    by getmoney517365 Mar 4, 2015 7:00 AM
    getmoney517365 getmoney517365 Mar 4, 2015 9:01 AM Flag

    Am I the only one seeing 1.28 in premarket?

  • getmoney517365 by getmoney517365 Mar 4, 2015 7:00 AM Flag


  • Reply to


    by getmoney517365 Feb 11, 2015 10:20 PM
    getmoney517365 getmoney517365 Feb 14, 2015 1:09 AM Flag

    Well I'd prefer to have news not happy next week since its a short week. Would love a bomb dropped on 02/23

  • getmoney517365 by getmoney517365 Feb 11, 2015 10:20 PM Flag

    So two more days and we are half way through February. Volume is dead. Am I the only one that is starting to doubt this big run this month? Would love to see the "explosion to 0.50-1.00." any day now. Just sayin. Thoughts on the dead silence, volume, lame news as of late? TIA

    Sentiment: Hold

2.47-0.04(-1.59%)Apr 24 4:00 PMEDT